These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 19920053)
1. Anemia and iron deficiency--new therapeutic targets in heart failure? Dec GW N Engl J Med; 2009 Dec; 361(25):2475-7. PubMed ID: 19920053 [No Abstract] [Full Text] [Related]
2. Ferric carboxymaltose in patients with heart failure and iron deficiency. Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P; N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054 [TBL] [Abstract][Full Text] [Related]
3. A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure. Osman M; Syed M; Balla S; Kheiri B; Faisaluddin M; Bianco C Am J Cardiol; 2021 Feb; 141():152-153. PubMed ID: 33259800 [No Abstract] [Full Text] [Related]
4. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy. Cases Amenós A; Ojeda López R; Portolés Pérez JM; Nefrologia; 2017; 37(6):587-591. PubMed ID: 28610806 [TBL] [Abstract][Full Text] [Related]
5. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722 [TBL] [Abstract][Full Text] [Related]
6. [Iron supplementation in chronic kidney disease]. Graczyk M; Dylewska M Wiad Lek; 2017; 70(6 pt 2):1215-1218. PubMed ID: 29533917 [TBL] [Abstract][Full Text] [Related]
7. Improved iron levels may help chronic heart failure. Mayo Clin Health Lett; 2010 Sep; 28(9):4. PubMed ID: 20928932 [No Abstract] [Full Text] [Related]
8. Ineffectiveness of iron polymaltose in treatment of iron deficiency anemia. Mehta BC J Assoc Physicians India; 2003 Apr; 51():419-21. PubMed ID: 12723665 [No Abstract] [Full Text] [Related]
9. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Hofmarcher T; Cabrales Alin D; Linde C Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358 [TBL] [Abstract][Full Text] [Related]
10. Clinical perspective: iron replacement therapy in chronic heart failure. Cowie MR; Lucas R Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435 [No Abstract] [Full Text] [Related]
11. Iron Deficiency in Heart Failure: An Overview. von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903 [TBL] [Abstract][Full Text] [Related]
12. [Iron deficiency : a new target in treating chronic heart failure ?]. Borgeaud M; Perrier A Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214 [TBL] [Abstract][Full Text] [Related]
13. IV iron in heart failure: theoretical concerns need clinical confirmation. Cowie MR; Lucas R Int J Clin Pract; 2011 Sep; 65(9):1014-5. PubMed ID: 21849013 [No Abstract] [Full Text] [Related]
14. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124 [TBL] [Abstract][Full Text] [Related]
15. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect]. Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771 [TBL] [Abstract][Full Text] [Related]
16. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970 [TBL] [Abstract][Full Text] [Related]
17. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia. Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838 [No Abstract] [Full Text] [Related]
18. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
19. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642 [TBL] [Abstract][Full Text] [Related]
20. [Economic impact of ferric carboxymaltose in haemodialysis patients]. Aiello A; Berto P; Conti P; Panichi V; Rosati A G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]